Among HER2 3 + BC patients, administration of adjuvant anti-HER2 in addition to chemotherapy significantly increased 10-year survival (P < 0.001 and P = 0.006, for BCSS and DMFS, respectively). Here, ERBB2 is linked to breast cancer.